Scholarlink

Background <p>Type 2 diabetes (T2D) affects 11.1% of the global population, underscoring the need for biomarkers that help characterize glycemic control status among treated individuals. We evaluated the association between the <i>FTO</i> variant rs9939609‑A and glycemic control in a Mexican population.</p> Methods <p>A total of 174 individuals living with T2D from Mérida and Sisal, Yucatán, were included, of whom 85% were receiving oral hypoglycemic agents as main treatment. Glycemic control was defined cross‑sectionally as good (≤ 130&#xa0;mg/dL, <i>n</i> = 63) or poor (&gt; 130&#xa0;mg/dL, <i>n</i> = 111) with fasting glucose. Linear mixed models incorporating relevant covariates and a family random intercept were used. Effect size estimates were transformed to logit odds ratios.</p> Results <p>After adjustment for age, sex, BMI, years since T2D diagnosis, and treatment, the minor allele of rs9939609 (A) was associated with an increased risk of poorer glycemic control, reaching significance under both the additive (OR = 1.145 [1.003–1.307], <i>p</i> = 0.047) and recessive (OR = 1.514 [1.026–2.234], <i>p</i> = 0.038) models. In an alternative model adjusting for waist circumference instead of BMI, the effect of rs9939609‑A in the additive model was slightly attenuated (OR = 1.135 [0.994–1.297], <i>p</i> = 0.063), while the recessive model remained significant (OR = 1.486 [1.010–2.189], <i>p</i> = 0.046).</p> Conclusions <p>rs9939609-A was associated with poorer glycemic control in this exploratory cohort, but replication in larger and ancestrally characterized samples is required.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Association of the FTO rs9939609 variant with glycemic control based on fasting glucose

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月7日

查看全文
  • Nicolas Fragoso-Bargas,
  • Rocio Vanessa Escarcega-Castro,
  • Irma Quintal-Ortiz,
  • Ligia Vera-Gamboa,
  • Guillermo Valencia-Pacheco,
  • Nina Valadez-Gonzalez

摘要

Background

Type 2 diabetes (T2D) affects 11.1% of the global population, underscoring the need for biomarkers that help characterize glycemic control status among treated individuals. We evaluated the association between the FTO variant rs9939609‑A and glycemic control in a Mexican population.

Methods

A total of 174 individuals living with T2D from Mérida and Sisal, Yucatán, were included, of whom 85% were receiving oral hypoglycemic agents as main treatment. Glycemic control was defined cross‑sectionally as good (≤ 130 mg/dL, n = 63) or poor (> 130 mg/dL, n = 111) with fasting glucose. Linear mixed models incorporating relevant covariates and a family random intercept were used. Effect size estimates were transformed to logit odds ratios.

Results

After adjustment for age, sex, BMI, years since T2D diagnosis, and treatment, the minor allele of rs9939609 (A) was associated with an increased risk of poorer glycemic control, reaching significance under both the additive (OR = 1.145 [1.003–1.307], p = 0.047) and recessive (OR = 1.514 [1.026–2.234], p = 0.038) models. In an alternative model adjusting for waist circumference instead of BMI, the effect of rs9939609‑A in the additive model was slightly attenuated (OR = 1.135 [0.994–1.297], p = 0.063), while the recessive model remained significant (OR = 1.486 [1.010–2.189], p = 0.046).

Conclusions

rs9939609-A was associated with poorer glycemic control in this exploratory cohort, but replication in larger and ancestrally characterized samples is required.